MILESTONE PHARMACEUTICALS: CURRENTLY PURSUING SINGLE-STUDY SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) REGISTRATION PATHWAY FOR TREATMENT OF AFIB-RVR

Reuters · 2d ago

Please log in to view news